GLP-1 Market
LLY $1425.17 ▼ -0.1% NVO $40.91 ▲ +0.6% PFE $28.77 ▼ -0.2% VKTX $26.80 ▼ -2.8% KLRA $12.92 ▼ -2.2% GPCR $19.24 ▼ -3.0% RHHBY $60.57 ▲ +0.0%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Dapagliflozin Tab

Company
Sherihan AboElyazed Mohamed Khalil
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 13, 2026

Find a Clinical Trial Near Me

See recruiting studies for Dapagliflozin Tab and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06281899

    Effect of Low Protein Diet on Top of Dapagliflozin on Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus

    Not yet reported Anemia Working Group Romania 200 participants Est. completion 2027-12-31 1 site Stand-alone
    Chronic kidney diseaseType 2 diabetes
    View official trial listing →
  • Recruiting NCT NCT06427226

    Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity

    Not yet reported Tanta University 46 participants Est. completion 2026-10-01 1 site
    Other conditions: Doxorubicin Induced Cardiomyopathy, Breast Cancer
    View official trial listing →
  • Completed NCT NCT04240171

    Dapagliflozin Versus Glimepiride Effect in Patient With Type 2 Diabetes Mellitus

    Damanhour University 60 participants Est. completion 2022-01-31 1 site
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT05392959

    Effect of the Antidiabetic Drug Dapagliflozin on the Coronary Macrovascular and Microvascular Function in Type 2 Diabetic Patients

    Not yet reported Centre Hospitalier Universitaire Saint Pierre 4 participants Est. completion 2023-07-17 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07891234

    Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance

    Not yet reported Sherihan AboElyazed Mohamed Khalil 66 participants Est. completion 2027-10-01 1 site
    Prediabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Dapagliflozin Tab, Dapagliflozin 5Mg Tab, PreDM/Dapa, Dapagliflozin 10 mg Tab

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.